Clinical Trials on Ovarian Cancer With Peritoneal Carcinosis

Total 3725 results

Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
zr Pharma & GmbH
Foundation Medicine

Completed

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United Kingdom, United States, Israel, Spain, Italy, Czechia, Canada, Hungary, Poland, Russian Federation, Brazil, Ukraine
Southeastern Gynecologic Oncology

Unknown

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Andrea McCart
Ontario Institute for Cancer Research

Withdrawn

Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin

Ovarian Cancer

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
Hospices Civils de Lyon

Completed

Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan

Peritoneal Carcinosis (PC)

France
University Health Network, Toronto

Terminated

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Bowel Obstruction

Canada
National Cancer Center, Korea

Completed

Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer

Ovarian Cancer

Korea, Republic of
Tata Memorial Centre

Recruiting

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Colorectal Cancer | Ovarian Cancer | Peritoneal Disease

India
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Shanghai Yunying Medical Technology
Shanghai 10th People's Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Mixed Mesodermal (Mullerian) Tumor | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage... and other conditions

United States, Korea, Republic of
Korean Gynecologic Oncology Group

Unknown

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Korea, Republic of
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | Peritoneal Cancer | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Merck Sharp & Dohme LLC

Terminated

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer
Eli Lilly and Company

Completed

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Fallopian Tube Neoplasms | Ovarian Cancer | Peritoneal Neoplasm

Spain, Poland, Belgium, Russian Federation, Germany
Far Eastern Memorial Hospital

Unknown

Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?

Peritoneal Dialysis

Taiwan
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Spain, Canada, Australia, United Kingdom, France
Clemens Tempfer

Completed

A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis

Ovarian Cancer

Germany
AbbVie (prior sponsor, Abbott)
Biogen

Completed

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Ovarian Cancer, Primary Peritoneal Cancer

United States, Australia, Belgium, Italy, Poland, Russian Federation, Spain, Sweden, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Centre Jean Perrin

Withdrawn

Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin (ISOTOVE)

Ovarian Cancer

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Genelux Corporation

Completed

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

United States
University of Southern California
Eli Lilly and Company; Aventis Pharmaceuticals

Completed

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

Peritoneal Neoplasms | Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Fatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditions

United States
Kristina Lindemann
University Hospital of North Norway; Haukeland University Hospital; Sorlandet... and other collaborators

Completed

Real-life Use of Niraparib in a Patient Access Program in Norway

Ovarian Cancer | Peritoneal Cancer

Norway
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Malignant... and other conditions

United States
University of Michigan Rogel Cancer Center

Terminated

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

Depression | Pain | Fatigue | Pseudomyxoma Peritonei | Peritoneal Carcinomatosis | Recurrent Endometrial Carcinoma | Anxiety Disorder | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Recurrent Breast Cancer | Leydig Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Ovarian... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Epithelial Ovarian Cancer

United States
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber...

Completed

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

SU5416 and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Peritoneal Neoplasm | Fallopian Tube Neoplasm

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
OHSU Knight Cancer Institute

Terminated

Abraxane/Bevacizumab

Ovarian Cancer | Peritoneal Cancer

United States
Eli Lilly and Company
Gynecologic Oncology Group

Completed

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer

Canada
National Cancer Institute (NCI)

Completed

TKM 080301 for Primary or Secondary Liver Cancer

Colorectal Cancer With Hepatic Metastases | Pancreas Cancer With Hepatic Metastase | Gastric Cancer With Hepatic Metastase | Breast Cancer With Hepatic Metastase | Ovarian Cancer With Hepatic Metastase

United States
Shattuck Labs, Inc.

Active, not recruiting

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma

United States, United Kingdom, Spain, Canada
Sheba Medical Center
Tel Aviv University

Withdrawn

Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies

Ovarian Cancer | Primary Peritoneal Cancer | Other Gynecological Cancers

Israel
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Clinical Trials on Ovarian Cancer With Peritoneal Carcinosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations